As far as financing fears, let me just point out that when, and I do mean WHEN, the share price goes up significantly on the next items of clinical trial news, it isn't going to take a sale of very many shares to keep the company comfortably funded when the current bucks (enough through next spring or summer) finally run out.

Or, of course, we could have a joint venture or upfront payments from a partner -- very common in biotech. Look at the deal Roche just pulled out of for another experimental antibiotic -- they put a huge amount of $$ out in advance.

Those bashers may be able to scare off some new investors but I sure don't see any of us selling -- not those of us who know what we own.